- Trials with a EudraCT protocol (12)
 - Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
 
		
	   		
	   		    
                    
                   	
                   	    12 result(s) found for: Electrolyte disorder.
                    
                
			
   			
		
		Displaying page 1 of 1.
	
	
| EudraCT Number: 2020-005605-93 | Sponsor Protocol Number: SILYCUS-21 | Start Date*: 2021-12-21 | |||||||||||
| Sponsor Name:ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.P.A. | |||||||||||||
| Full Title: Efficacy and safety of Silycus® in Cushing’s disease: a multicenter, single arm, open label, dose titration, proof of concept study (Silycus®-21) | |||||||||||||
| Medical condition: Cushing's disease | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004420-30 | Sponsor Protocol Number: CL3-95008-002 | Start Date*: 2018-10-04 | |||||||||||
| Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
| Full Title: Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled mult... | |||||||||||||
| Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Not Authorised) HU (Completed) PT (Completed) PL (Prematurely Ended) IE (Prematurely Ended) CZ (Completed) SK (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-004558-18 | Sponsor Protocol Number: 20000178 | Start Date*: 2005-02-11 | 
| Sponsor Name:Amgen Inc | ||
| Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects with Secondary Hyperparathyroidism Not Receiving Dialysis | ||
| Medical condition: Secondary Hyperparathyroidism in Chronic Kidney Disease subjects not receiving dialysis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Prematurely Ended) NO (Completed) DK (Completed) IT (Prematurely Ended) ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-004419-38 | Sponsor Protocol Number: CL3-95008-001 | Start Date*: 2018-10-04 | |||||||||||
| Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
| Full Title: Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, place... | |||||||||||||
| Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Completed) ES (Prematurely Ended) NL (Completed) HU (Completed) PT (Completed) PL (Prematurely Ended) IT (Completed) IE (Prematurely Ended) CZ (Ongoing) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003873-13 | Sponsor Protocol Number: ESR-14-10613/D1690L00044 | Start Date*: 2016-02-25 | |||||||||||
| Sponsor Name:Institute for the Study, Research and Education in Diabetes Mellitus and Metabolic Disorders | |||||||||||||
| Full Title: Evaluation of the tubular effects of dapagliflozin using 1HNMR spectroscopy. | |||||||||||||
| Medical condition: Diabetes mellitus type 2. | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-000749-19 | Sponsor Protocol Number: SPON934-11 | Start Date*: 2011-06-29 | |||||||||||
| Sponsor Name:Cardiff University | |||||||||||||
| Full Title: Bloodwise and NCRI Working Group Pick a Winner Programme (LI-1) Trial | |||||||||||||
| Medical condition: Acute myeloid leukemia and high-risk myelodysplastic syndrome | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-002721-99 | Sponsor Protocol Number: CT114-2022-01 | Start Date*: 2023-03-28 | |||||||||||
| Sponsor Name:Klinikum Nürnberg | |||||||||||||
| Full Title: Natriuretic-ureothelic adaptation of body fluid homeostasis during SGLT-2 inhibition and/or mineralocorticoid receptor modulation in patients with chronic kidney disease. A 4-arm, double-blind, dou... | |||||||||||||
| Medical condition: Stage 3 chronic kidney disease | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-003177-58 | Sponsor Protocol Number: SPIOMET4HEALTH | Start Date*: 2022-05-12 | |||||||||||
| Sponsor Name:Fundació Sant Joan de Déu (FSJD) | |||||||||||||
| Full Title: A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIO... | |||||||||||||
| Medical condition: Polycystic Ovary Syndrome (PCOS) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: AT (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-004460-39 | Sponsor Protocol Number: 248.644 | Start Date*: 2008-11-11 | |||||||||||
| Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.0625-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age... | |||||||||||||
| Medical condition: Tourette's Syndrome | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-000342-32 | Sponsor Protocol Number: 248.642 | Start Date*: 2009-02-17 | |||||||||||
| Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
| Full Title: An open-label, flexible dose, follow-up study to evaluate safety and efficacy of oral pramipexole (0.0625-0.5 mg/day) for 24 weeks in children and adolescents (age 6-17 years) diagnosed with Touret... | |||||||||||||
| Medical condition: Tourette's Syndrome | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-002730-21 | Sponsor Protocol Number: SPON1227-13 | Start Date*: 2013-11-25 | |||||||||||
| Sponsor Name:Cardiff University | |||||||||||||
| Full Title: A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome | |||||||||||||
| Medical condition: Acute Myeloid Leukaemia High Risk Myelodysplastic Syndrome | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001048-40 | Sponsor Protocol Number: B1371013 | Start Date*: 2015-02-10 | |||||||||||
| Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017 | |||||||||||||
| Full Title: A phase 2, double-blind, randomized safety and efficacy study of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis previously treated with ruxolitinib. | |||||||||||||
| Medical condition: Myelofibrosis | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) ES (Completed) AT (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
    	Query did not match any studies.